Literature DB >> 19785525

Encapsulated Bacillus anthracis interacts closely with liver endothelium.

Alejandro Piris-Gimenez1, Jean-Philippe Corre, Gregory Jouvion, Thomas Candela, Huot Khun, Pierre L Goossens.   

Abstract

BACKGROUND: The Bacillus anthracis poly-gamma-D-glutamate capsule is essential for virulence. It impedes phagocytosis and protects bacilli from the immune system, thus promoting systemic dissemination.
METHODS: To further define the virulence mechanisms brought into play by the capsule, we characterized the interactions between encapsulated nontoxinogenic B. anthracis and its host in vivo through histological analysis, perfusion, and competition experiments with purified capsule.
RESULTS: Clearance of encapsulated bacilli from the blood was rapid (>90% clearance within 5 min), with 75% of the bacteria being trapped in the liver. Competition experiments with purified capsule polyglutamate inhibited this interaction. At the septicemic phase of cutaneous infection with spores, the encapsulated bacilli were trapped in the vascular spaces of the liver and interacted closely with the liver endothelium in the sinusoids and terminal and portal veins. They often grow as microcolonies containing capsular material shed by the bacteria.
CONCLUSION: We show that, in addition to its inhibitory effect on the interaction with the immune system, the capsule surrounding B. anthracis plays an active role in mediating the trapping of the bacteria within the liver and may thus contribute to anthrax pathogenesis. Because other microorganisms produce polyglutamate, it may also represent a general mechanism of virulence or in vivo survival.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19785525     DOI: 10.1086/644506

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

Review 1.  New insights into the biological effects of anthrax toxins: linking cellular to organismal responses.

Authors:  Annabel Guichard; Victor Nizet; Ethan Bier
Journal:  Microbes Infect       Date:  2011-09-08       Impact factor: 2.700

2.  Inter-α inhibitor proteins: a novel therapeutic strategy for experimental anthrax infection.

Authors:  Steven M Opal; Yow-Pin Lim; Patricia Cristofaro; Andrew W Artenstein; Noubar Kessimian; David Delsesto; Nicolas Parejo; John E Palardy; Edward Siryaporn
Journal:  Shock       Date:  2011-01       Impact factor: 3.454

3.  Noninvasive imaging technologies reveal edema toxin as a key virulence factor in anthrax.

Authors:  Fabien Dumetz; Grégory Jouvion; Huot Khun; Ian Justin Glomski; Jean-Philippe Corre; Clémence Rougeaux; Wei-Jen Tang; Michèle Mock; Michel Huerre; Pierre Louis Goossens
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

Review 4.  Surviving Between Hosts: Sporulation and Transmission.

Authors:  Michelle C Swick; Theresa M Koehler; Adam Driks
Journal:  Microbiol Spectr       Date:  2016-08

5.  Clindamycin Protects Nonhuman Primates Against Inhalational Anthrax But Does Not Enhance Reduction of Circulating Toxin Levels When Combined With Ciprofloxacin.

Authors:  Nicholas J Vietri; Steven A Tobery; Donald J Chabot; Susham Ingavale; Brandon C Somerville; Jeremy A Miller; Chris W Schellhase; Nancy A Twenhafel; David P Fetterer; Christopher K Cote; Christopher P Klimko; Anne E Boyer; Adrian R Woolfitt; John R Barr; Mary E Wright; Arthur M Friedlander
Journal:  J Infect Dis       Date:  2021-02-03       Impact factor: 5.226

6.  Capsules, toxins and AtxA as virulence factors of emerging Bacillus cereus biovar anthracis.

Authors:  Christophe Brézillon; Michel Haustant; Susann Dupke; Jean-Philippe Corre; Angelika Lander; Tatjana Franz; Marc Monot; Evelyne Couture-Tosi; Gregory Jouvion; Fabian H Leendertz; Roland Grunow; Michèle E Mock; Silke R Klee; Pierre L Goossens
Journal:  PLoS Negl Trop Dis       Date:  2015-04-01

Review 7.  Anthrax prophylaxis: recent advances and future directions.

Authors:  E Diane Williamson; Edward Hugh Dyson
Journal:  Front Microbiol       Date:  2015-09-24       Impact factor: 5.640

Review 8.  Crossing of the epithelial barriers by Bacillus anthracis: the Known and the Unknown.

Authors:  Pierre L Goossens; Jean-Nicolas Tournier
Journal:  Front Microbiol       Date:  2015-10-09       Impact factor: 5.640

Review 9.  Possible use of bacteriophages active against Bacillus anthracis and other B. cereus group members in the face of a bioterrorism threat.

Authors:  Ewa Jończyk-Matysiak; Marlena Kłak; Beata Weber-Dąbrowska; Jan Borysowski; Andrzej Górski
Journal:  Biomed Res Int       Date:  2014-08-28       Impact factor: 3.411

Review 10.  Raxibacumab: potential role in the treatment of inhalational anthrax.

Authors:  Carlos E Kummerfeldt
Journal:  Infect Drug Resist       Date:  2014-04-29       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.